<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Valirx Plc — News on 6ix</title>
<link>https://6ix.com/company/valirx-plc</link>
<description>Latest news and press releases for Valirx Plc on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Tue, 31 Mar 2026 09:15:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/valirx-plc" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo6835eee478dffbe2df12c38d.webp</url>
<title>Valirx Plc</title>
<link>https://6ix.com/company/valirx-plc</link>
</image>
<item>
<title>Change of Registered Office</title>
<link>https://6ix.com/company/valirx-plc/news/change-of-registered-office-197</link>
<guid isPermaLink="true">https://6ix.com/company/valirx-plc/news/change-of-registered-office-197</guid>
<pubDate>Tue, 31 Mar 2026 09:15:00 GMT</pubDate>
<description>ValiRx Plc has announced a change to its registered office, relocating to 20 Wenlock Road, London, England, N1 7GU. This administrative update does not involve any financial figures or operational changes that would directly impact the company's stock share price.
Disclaimer*</description>
</item>
<item>
<title>ValiRx Commercial Update Q1 2026</title>
<link>https://6ix.com/company/valirx-plc/news/valirx-commercial-update-q1-2026</link>
<guid isPermaLink="true">https://6ix.com/company/valirx-plc/news/valirx-commercial-update-q1-2026</guid>
<pubDate>Thu, 26 Mar 2026 07:00:00 GMT</pubDate>
<description>ValiRx PLC reported a Q1 2026 commercial update, achieving £42,500 in annual operational savings through voluntary salary reductions and advisory board changes. The company expanded its pipeline by signing two preclinical evaluation agreements, including one with McGill University and IRICoR, and established ValiRx Animal Health Ltd (VAH) as a subsidiary to commercialise oncology assets in the veterinary market, with discussions underway for venture funding. ValiRx is also filing for patent prot</description>
</item>
<item>
<title>ValiRx and TwinEdge to present Digital Twin data</title>
<link>https://6ix.com/company/valirx-plc/news/valirx-and-twinedge-to-present-digital-twin-data</link>
<guid isPermaLink="true">https://6ix.com/company/valirx-plc/news/valirx-and-twinedge-to-present-digital-twin-data</guid>
<pubDate>Tue, 24 Mar 2026 07:00:00 GMT</pubDate>
<description>ValiRx PLC announced that it, along with TwinEdge Bioscience and its subsidiary Inaphaea Biolabs, will present an abstract at the American Association of Cancer Research on April 22, 2026, detailing their work on integrating omics-driven digital avatars with patient-derived experimental models to accelerate precision oncology. Inaphaea was also invited to publish an editorial on patient-derived models in Drug Discovery World Spring 2026, and ValiRx co-authored an article in Epigenomics discussin</description>
</item>
<item>
<title>ValiRx forms ValiRx Animal Health Ltd subsidiary</title>
<link>https://6ix.com/company/valirx-plc/news/valirx-forms-valirx-animal-health-ltd-subsidiary</link>
<guid isPermaLink="true">https://6ix.com/company/valirx-plc/news/valirx-forms-valirx-animal-health-ltd-subsidiary</guid>
<pubDate>Mon, 02 Mar 2026 07:00:00 GMT</pubDate>
<description>ValiRx PLC has established a wholly owned subsidiary, ValiRx Animal Health Limited, to develop and commercialise its oncology assets within the veterinary market, leveraging the scientific rationale that canine tumours closely resemble human cancers. This strategic move aims to unlock earlier commercial opportunities by partnering with veterinary pharmaceutical companies, with the intention of independent funding for ValiRx Vet. The global veterinary oncology market is experiencing significant g</description>
</item>
<item>
<title>Exercise of Warrants</title>
<link>https://6ix.com/company/valirx-plc/news/exercise-of-warrants-32</link>
<guid isPermaLink="true">https://6ix.com/company/valirx-plc/news/exercise-of-warrants-32</guid>
<pubDate>Mon, 19 Jan 2026 07:00:00 GMT</pubDate>
<description>ValiRx PLC has announced the exercise of warrants for 80,000 ordinary shares at 0.5 pence per share, generating gross proceeds of £400. These new ordinary shares will be admitted to trading on AIM around January 23, 2026, and will rank pari passu with existing shares. Following this issuance, the company's enlarged issued share capital will consist of 742,801,072 ordinary shares.
Disclaimer*</description>
</item>
<item>
<title>Replacement: Evaluation and Transfer Agreement</title>
<link>https://6ix.com/company/valirx-plc/news/replacement-evaluation-and-transfer-agreement</link>
<guid isPermaLink="true">https://6ix.com/company/valirx-plc/news/replacement-evaluation-and-transfer-agreement</guid>
<pubDate>Fri, 09 Jan 2026 15:45:00 GMT</pubDate>
<description>ValiRx PLC has entered into a nine-month Evaluation and Material Transfer Agreement with McGill University and IRICoR to establish the target engagement and potency of a second-generation RNA Helicase inhibitor, with ValiRx owning any generated evaluation results. IRICoR will establish a subsidiary, NewCo, to commercialize these results, and ValiRx has an option to license the evaluation results into NewCo for a pre-agreed equity holding. ValiRx may also provide up to £2 million in seed funding </description>
</item>
<item>
<title>New Evaluation and Material Transfer Agreement</title>
<link>https://6ix.com/company/valirx-plc/news/new-evaluation-and-material-transfer-agreement</link>
<guid isPermaLink="true">https://6ix.com/company/valirx-plc/news/new-evaluation-and-material-transfer-agreement</guid>
<pubDate>Fri, 09 Jan 2026 07:00:00 GMT</pubDate>
<description>ValiRx PLC has entered into a nine-month Evaluation and Material Transfer Agreement with McGill University and IRICoR to assess a second-generation RNA Helicase inhibitor, with ValiRx's subsidiary Inaphaea Biolabs Ltd conducting the evaluation and owning any generated results. ValiRx has an option to license these results into a newly formed subsidiary, NewCo, for a 15% equity stake, and may provide up to £2 million in seed funding in exchange for further equity, with other funding sources dilut</description>
</item>
<item>
<title>Holding(s) in Company</title>
<link>https://6ix.com/company/valirx-plc/news/holdings-in-company-354</link>
<guid isPermaLink="true">https://6ix.com/company/valirx-plc/news/holdings-in-company-354</guid>
<pubDate>Thu, 08 Jan 2026 13:00:00 GMT</pubDate>
<description>Jaspal Singh has reduced their holding in ValiRx PLC, with their voting rights now standing at 2.96%, down from a previous notification of 4.51%. This change, representing 22,000,000 voting rights, was effective on January 5, 2026, and the company was notified on January 8, 2026. No financial instruments with similar economic effects were reported.
Disclaimer*</description>
</item>
<item>
<title>Result of GM & Issue of Equity</title>
<link>https://6ix.com/company/valirx-plc/news/result-of-gm-and-issue-of-equity</link>
<guid isPermaLink="true">https://6ix.com/company/valirx-plc/news/result-of-gm-and-issue-of-equity</guid>
<pubDate>Thu, 20 Nov 2025 12:11:00 GMT</pubDate>
<description>ValiRx Plc announced that all resolutions were passed at its General Meeting, leading to the allotment of 256,067,800 new shares, with admission to AIM expected on November 21, 2025. The company also issued 368,372,400 Fundraising Warrants and 16,036,120 Broker Warrants. Following these transactions, the enlarged issued share capital will comprise 742,721,072 ordinary shares. Directors Mark Eccleston, Cathy Tralau-Stewart, Gerry Desler, and Martin Gouldstone participated in the fundraising, acqu</description>
</item>
<item>
<title>Posting of Circular and Notice of General Meeting</title>
<link>https://6ix.com/company/valirx-plc/news/posting-of-circular-and-notice-of-general-meeting-18</link>
<guid isPermaLink="true">https://6ix.com/company/valirx-plc/news/posting-of-circular-and-notice-of-general-meeting-18</guid>
<pubDate>Tue, 04 Nov 2025 17:15:00 GMT</pubDate>
<description>Posting of Circular and Notice of General Meeting.</description>
</item>
<item>
<title>Result of WRAP Retail Offer</title>
<link>https://6ix.com/company/valirx-plc/news/result-of-wrap-retail-offer-4</link>
<guid isPermaLink="true">https://6ix.com/company/valirx-plc/news/result-of-wrap-retail-offer-4</guid>
<pubDate>Tue, 04 Nov 2025 07:00:00 GMT</pubDate>
<description>Result of WRAP Retail Offer.</description>
</item>
<item>
<title>WRAP Retail Offer for up to £300,000</title>
<link>https://6ix.com/company/valirx-plc/news/wrap-retail-offer-for-up-to-pound300000</link>
<guid isPermaLink="true">https://6ix.com/company/valirx-plc/news/wrap-retail-offer-for-up-to-pound300000</guid>
<pubDate>Thu, 30 Oct 2025 07:21:00 GMT</pubDate>
<description>ValiRx PLC announced a retail offer via the Winterflood Retail Access Platform (WRAP) to raise up to £300,000 through the issue of new ordinary shares at a price of 0.25 pence per share, totaling up to 120,000,000 new ordinary shares. One warrant will be granted for every share, allowing the holder to acquire one new ordinary share at 0.50 pence up to the third anniversary of the Tranche 2 Placing Shares' admission to trading on AIM. The company has conditionally raised £750,000 through the Plac</description>
</item>
<item>
<title>Fundraising of up to £1,050,000</title>
<link>https://6ix.com/company/valirx-plc/news/fundraising-of-up-to-pound1050000</link>
<guid isPermaLink="true">https://6ix.com/company/valirx-plc/news/fundraising-of-up-to-pound1050000</guid>
<pubDate>Thu, 30 Oct 2025 07:17:00 GMT</pubDate>
<description>ValiRx PLC announced a fundraising effort to raise up to £1,050,000 before expenses. This includes a placing of 112,304,600 Tranche 1 placing shares and a conditional placing of 183,695,400 Tranche 2 placing shares. There is also a conditional WRAP Retail Offer for up to 120,000,000 new shares, conditional director subscriptions for 4,000,000 shares, and conditional fee shares of 7,650,000, all at an issue price of 0.25 pence per share. The company will conditionally issue up to 427,650,000 fund</description>
</item>
<item>
<title>Inaphaea Commercial update</title>
<link>https://6ix.com/company/valirx-plc/news/inaphaea-commercial-update</link>
<guid isPermaLink="true">https://6ix.com/company/valirx-plc/news/inaphaea-commercial-update</guid>
<pubDate>Tue, 14 Oct 2025 06:00:00 GMT</pubDate>
<description>ValiRx PLC announced a commercial update for its subsidiary Inaphaea Limited. Inaphaea completed the second phase of its service contract with Amply Discovery Limited, receiving a balancing payment of approximately £31,000. Following a Knowledge Transfer Voucher award, the academic partner received a £250,000 UKRI grant to further develop its in-silico spheroid modelling platform, with Inaphaea supplying Patient Derived Cells. Furthermore, Inaphaea has signed an agreement with Apis Assay Technol</description>
</item>
<item>
<title>Half-year Report</title>
<link>https://6ix.com/company/valirx-plc/news/half-year-report-175</link>
<guid isPermaLink="true">https://6ix.com/company/valirx-plc/news/half-year-report-175</guid>
<pubDate>Mon, 29 Sep 2025 06:00:00 GMT</pubDate>
<description>ValiRx PLC announced its unaudited half-yearly report for the period ended 30 June 2025. Research and development costs were £105,489, while administrative expenses totaled £828,444. The company reported a loss before income taxation of £931,135 and a total comprehensive loss for the period of £838,434, equating to a loss per share from continuing operations of 0.22p. Cash and cash equivalents stood at £518,794 as of 30 June 2025. Post period R&D tax credits of £138,000 have been received. The c</description>
</item>
<item>
<title>Inaphaea Commercial Update</title>
<link>https://6ix.com/company/valirx-plc/news/inaphaea-commercial-update-1</link>
<guid isPermaLink="true">https://6ix.com/company/valirx-plc/news/inaphaea-commercial-update-1</guid>
<pubDate>Thu, 18 Sep 2025 06:00:00 GMT</pubDate>
<description>ValiRx PLC's subsidiary, Inaphaea, has signed a Collaboration Agreement with TwinEdge Bioscience to create "patient avatars" using Inaphaea's Patient Derived Cells (PDCs) and TwinEdge's AI platform. Inaphaea also signed a Material Transfer Agreement with Nottingham University Hospitals NHS Trust for new PDC models, focusing on ovarian, breast, lung, and prostate cancer samples. Additionally, six colorectal Cancer PDC models were transferred to Cellomatics Ltd under the Evaluation Use Agreement. </description>
</item>
<item>
<title>Cytolytix Commercial update</title>
<link>https://6ix.com/company/valirx-plc/news/cytolytix-commercial-update</link>
<guid isPermaLink="true">https://6ix.com/company/valirx-plc/news/cytolytix-commercial-update</guid>
<pubDate>Mon, 01 Sep 2025 06:00:00 GMT</pubDate>
<description>ValiRx PLC announced that its majority-owned subsidiary, Cytolytix, received a notice of allowance for the European Patent application No. 21798092.9, concerning a nanoparticle for anti-cancer peptides. Claims within European Patent Application No. 20793085.0, "Polyleucine-Based Peptides As Anti-Cancer Agents" are considered allowable, and an accelerated examination has been requested. Cytolytix has completed development of its second-generation delivery platform and scheduled materials for eval</description>
</item>
<item>
<title>Commercial update</title>
<link>https://6ix.com/company/valirx-plc/news/commercial-update-3</link>
<guid isPermaLink="true">https://6ix.com/company/valirx-plc/news/commercial-update-3</guid>
<pubDate>Tue, 26 Aug 2025 06:00:00 GMT</pubDate>
<description>ValiRx PLC announced the establishment of a new wholly-owned subsidiary, Blue Ribbon Bio Limited, to house all Prostate Cancer associated assets, initially consisting of existing Intellectual Property for Val201, exclusively licensed to ValiRx by Cancer Research Horizons in 2010. The company plans to file new application-based patents for Val201, which will be held by Blue Ribbon. A technical and market assessment concluded a strong rationale for Val201 within prostate cancer treatment. Addition</description>
</item>
<item>
<title>ValiRx Awarded Grant from Open University</title>
<link>https://6ix.com/company/valirx-plc/news/valirx-awarded-grant-from-open-university</link>
<guid isPermaLink="true">https://6ix.com/company/valirx-plc/news/valirx-awarded-grant-from-open-university</guid>
<pubDate>Thu, 07 Aug 2025 09:51:00 GMT</pubDate>
<description>ValiRx Awarded Grant from Open University.</description>
</item>
<item>
<title>Update on Evaluation Agreement with Stingray Bio</title>
<link>https://6ix.com/company/valirx-plc/news/update-on-evaluation-agreement-with-stingray-bio</link>
<guid isPermaLink="true">https://6ix.com/company/valirx-plc/news/update-on-evaluation-agreement-with-stingray-bio</guid>
<pubDate>Tue, 05 Aug 2025 08:53:00 GMT</pubDate>
<description>Update on Evaluation Agreement with Stingray Bio.</description>
</item>
</channel>
</rss>